Generic name:piflufolastat f 18 (intravenous route) [ pif-loo-FOE-la-stat-F-18 ]
Drug class:Diagnostic radiopharmaceuticals
Medically reviewed by Drugs.com. Last updated on Apr 27, 2022.
Commonly used brand name(s)
In the U.S.
- Pylarify
Available Dosage Forms:
- Solution
Therapeutic Class: Diagnostic Agent, Radiopharmaceutical Imaging
Uses for Pylarify
Piflufolastat F 18 injection is used with a PET scan (positron emission tomography) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is given in patients with suspected metastasis (cancer that has spread to the other parts of the body) who are candidates for initial treatment and with suspected recurrence (cancer that keeps coming back) based on an increased serum prostate-specific antigen (PSA) level.
Piflufolastat F 18 is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents, which may be used to find and treat certain diseases or to study the function of the body's organs.
This medicine is to be given only by or under the direct supervision of a doctor with specialized training in nuclear medicine.
Before using Pylarify
In deciding to use a diagnostic test, any risks of the test must be weighed against the good it will do. This is a decision you and your doctor will make. Also, other things may affect test results. For this test, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of piflufolastat F 18 injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies perform...
